- Home
- MDXH vs IPHA Comparison
MDXH vs IPHA Comparison
Compare MDXH & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDXH | IPHA |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | Belgium | France |
| Employees | N/A | 174 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.4M | 160.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MDXH | IPHA |
|---|---|---|
| Price | $3.31 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $7.67 | $5.00 |
| AVG Volume (30 Days) | ★ 112.8K | 16.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.31 | $28.31 |
| Revenue Next Year | $18.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.36 | $1.57 |
| 52 Week High | $5.33 | $2.63 |
Technical Indicators
Market Signals| Indicator | MDXH | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 44.30 |
| Support Level | $3.05 | $1.60 |
| Resistance Level | $3.78 | $1.86 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 17.92 | 27.04 |
Price Performance
Historical ComparisonAbout MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.